Gemmer Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-1,000
| Closed | -$18K | – | 1495 |
|
|
2018
Q3 | $18K | Sell |
1,000
-500
| -33% | -$8.58K | 0.01% | 452 |
|
|
2018
Q2 | $21K | Hold |
1,500
| – | – | 0.01% | 399 |
|
|
2018
Q1 | $14K | Hold |
1,500
| – | – | ﹤0.01% | 553 |
|
|
2017
Q4 | $6K | Hold |
1,500
| – | – | ﹤0.01% | 934 |
|
|
2017
Q3 | $2K | Hold |
1,500
| – | – | ﹤0.01% | 1212 |
|
|
2017
Q2 | $2K | Hold |
1,500
| – | – | ﹤0.01% | 1203 |
|
|
2017
Q1 | $4K | Hold |
1,500
| – | – | ﹤0.01% | 1035 |
|
|
2016
Q4 | $4K | Hold |
1,500
| – | – | ﹤0.01% | 1031 |
|
|
2016
Q3 | $5K | Hold |
1,500
| – | – | ﹤0.01% | 921 |
|
|
2016
Q2 | $5K | Hold |
1,500
| – | – | ﹤0.01% | 894 |
|
|
2016
Q1 | $4K | Hold |
1,500
| – | – | ﹤0.01% | 924 |
|
|
2015
Q4 | $6K | Hold |
1,500
| – | – | ﹤0.01% | 806 |
|
|
2015
Q3 | $7K | Hold |
1,500
| – | – | ﹤0.01% | 703 |
|
|
2015
Q2 | $8K | Hold |
1,500
| – | – | ﹤0.01% | 674 |
|
|
2015
Q1 | $9K | Hold |
1,500
| – | – | 0.01% | 682 |
|
|
2014
Q4 | $9K | Hold |
1,500
| – | – | 0.01% | 654 |
|
|
2014
Q3 | $9K | Buy |
1,500
+500
| +50% | +$3.42K | 0.01% | 630 |
|
|
2014
Q2 | $7K | Buy |
1,000
+500
| +100% | +$5.63K | ﹤0.01% | 808 |
|
|
2014
Q1 | $12K | Buy |
+500
| New | +$7.25K | 0.01% | 505 |
|
Other funds holding ECYT
Gemmer Asset Management's ECYT Position: Q4 2018 in Review
Gemmer Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,000 shares — an estimated $18K sold.
Gemmer Asset Management first reported a position in ECYT in Q1 2014 and held it in 19 quarters. The position peaked at $21K in Q2 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Gemmer Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Gemmer Asset Management sold 1,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $18K.
- Gemmer Asset Management first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 19 quarters.
- Gemmer Asset Management's Endocyte, Inc. Common Stock position peaked at $21K in Q2 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Gemmer Asset Management's 13F filing for Q4 2018, filed 18 Jan 2019.